Answers are grounded in this paper and cite their sources.
583 Background: Myl-1401O is a proposed trastuzumab biosimilar. The biosimilarity of Myl-1401O to EU-Herceptin has been demonstrated in physicochemical analyses, nonclinical studies, and one previous PK study. Methods: This single-center, randomized, double-blind, three-arm, parallel-group, Phase I study was conducted in healthy adult male volunteers. The primary objective of this study was to establish PK similarity of A to B and C. The subjects were randomized to receive either A, B or C as 8 mg/kg over 90 minutes as an intravenous infusion. For the primary endpoint, the bioequivalence criterion was that the 90% confidence intervals (CI) of the mean ratios of AUC0-∞ , AUC0-last , and Cmax were bounded within 80.00% - 125.00% calculated using natural log-transformed data. As secondary endpoints, λz, tmax and t1/2 along with assessment of safety (including immunogenicity) was performed. Results: A total of 132 subjects (44/treatment) were enrolled and 120 [42 (A), 41(B), 37(C)] subjects were included in analysis. Statistical analyses reveal that the 90% CI fall within 80%-125% for all parameters. Eighty-three [31 (A), 28 (B), 24(C)] subjects experienced a total of 227 [91(A), 80 (B), 56(C)] treatment-emergent adverse events that were mild to moderate in severity. No serious adverse events were reported and there were no instances of treatment related anti-drug antibodies. Conclusions: These results confirm pharmacokinetic bioequivalence for Myl-1401O vs. EU-Herceptin and US-Herceptin. All treatments were well tolerated and no significant safety issues emerged. Clinical trial information: NCT02594761.PK results (dose-normalized) AUC0-last (mcg•hr/mL) AUC0-∞ (mcg•hr/mL) Cmax (mcg/mL) Arithmetic Mean (%CV) A N = 42 48055 (15.92) 48241 (16.19) 200.4 (12.34) B N = 41 49823 (19.61) 50075 (19.81) 192.6 (14.13) C N = 37 49826 (13.98) 50181 (13.86) 197.9 (16.25) LSMEANS Ratio* (90% CI)** A/B 0.97 (91.31% – 103.05%) 0.97 (91.17% – 102.97%) 1.04 (99.00% – 109.82%) A/C 0.96 (90.34% – 102.29%) 0.96 (89.96% – 101.94%) 1.02 (96.42% – 107.26%) * Ratio (A/B) = e [LSMEANS of (LNA – LNB)]; Ratio (A/C) = e [LSMEANS of (LNA – LNC)]; **Used Natural Log Transformed Parameter
No takes yet. Share an insight, caveat, or question.
Waller et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: